New photobiomodulation device for prevention and cure of radiotherapy-induced oral mucositis and dermatitis: results of the prospective Safe PBM study

René-Jean Bensadoun, Marc A Bollet, Xavier Liem, Kim Cao, Nicolas Magné, René-Jean Bensadoun, Marc A Bollet, Xavier Liem, Kim Cao, Nicolas Magné

Abstract

Purpose: The study aims to assess the feasibility, safety, and tolerability of CareMin650, a new photobiomodulation device, in patients treated by radiotherapy (RT) and to collect preliminary data on efficacy for prevention and treatment of oral mucositis (OM) and radiation dermatitis (RD).

Methods: Safe PBM is a French, multicentric, prospective, non-comparative study which include patients with head and neck cancer (H&NC, cohort A) or breast cancer (BC, cohort B) treated in prophylactic (cohorts A1 and B1) or curative setting (cohort A2 and B2). Prophylactic treatment was administered from D1 to end of RT, at a dose of 3 J/cm2. Curative treatment started when a grade 1 to grade 3 lesion had occurred and was pursued until end of RT. Primary endpoint was incidence of device-related adverse events (AEs). OM and RD lesions were graded according to CTCAE V3.

Results: Overall, 72 patients were included (22, 9, 23, and 18 in cohorts A1, A2, B1, and B2, respectively). No device-related AE was reported after 1312 CareMin650 sessions. In cohorts A1 and B1, median time to first OM or RD lesion was 20 days. One BC patient developed G3 RD after completion of RT and discontinuation of CareMin650. Four H&NC patients developed G3 OM. In cohorts A2 and B2, lesions improved or stabilized in 71% of patients. Rates of satisfaction were high among patients and users.

Conclusion: CareMin650 is feasible, safe, and well tolerated for preventive or curative treatment of OM and RD in cancer patients treated with RT. Preliminary efficacy results are promising.

Keywords: Breast cancer; Head and neck cancer; Oral mucositis; Photobiomodulation; Radiation dermatitis.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Figures

Fig. 1
Fig. 1
CareMin650. A Light box and oral pads. B Light box and derma pad. C Oral pads placed in the mouth. D Derma pad placed on the neck
Fig. 2
Fig. 2
Disposition of patients

References

    1. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–1461. doi: 10.1002/cncr.28592.
    1. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis. 2006;12(3):229–241. doi: 10.1111/j.1601-0825.2006.01258.x.
    1. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–262. doi: 10.1016/S0167-8140(02)00404-8.
    1. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–1120. doi: 10.1016/j.ijrobp.2007.01.053.
    1. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009;38(4):522–532. doi: 10.1016/j.jpainsymman.2008.12.004.
    1. Antunes HS, Herchenhorn D, Small IA, et al. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol. 2013;109(2):297–302. doi: 10.1016/j.radonc.2013.08.010.
    1. Antunes HS, Herchenhorn D, Small IA, et al. Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncol. 2017;71:11–15. doi: 10.1016/j.oraloncology.2017.05.018.
    1. Bensadoun RJ, Franquin JC, Ciais G, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer. 1999;7(4):244–52. doi: 10.1007/s005200050256.
    1. Gautam AP, Fernandes DJ, Vidyasagar MS, Maiya AG, Vadhiraja BM. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients — a triple blinded randomized controlled trial. Radiother Oncol. 2012;104(3):349–354. doi: 10.1016/j.radonc.2012.06.011.
    1. Oton-Leite AF, Elias LS, Morais MO, et al. Effect of low level laser therapy in the reduction of oral complications in patients with cancer of the head and neck submitted to radiotherapy. Spec Care Dentist. 2013;33(6):294–300. doi: 10.1111/j.1754-4505.2012.00303.x.
    1. Gautam AP, Fernandes DJ, Vidyasagar MS, Maiya AG, Guddattu V. Low level laser therapy against radiation induced oral mucositis in elderly head and neck cancer patients—a randomized placebo controlled trial. J Photochem Photobiol B. 2015;144:51–56. doi: 10.1016/j.jphotobiol.2015.01.011.
    1. Elad S, Cheng KKF, Lalla RV et al (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126(19):4423–4431
    1. Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3969–3983. doi: 10.1007/s00520-019-04890-2.
    1. Seite S, Bensadoun RJ, Mazer JM. Prevention and treatment of acute and chronic radiodermatitis. Breast Cancer (Dove Med Press) 2017;9:551–557.
    1. Wong RK, Bensadoun RJ, Boers-Doets CB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013;21(10):2933–2948. doi: 10.1007/s00520-013-1896-2.
    1. Kole AJ, Kole L, Moran MS. Acute radiation dermatitis in breast cancer patients: challenges and solutions. Breast Cancer (Dove Med Press) 2017;9:313–323.
    1. Robijns J, Censabella S, Claes S et al (2018) Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial). Lasers Surg Med 50(7):763–771
    1. Hamblin MR, Victor Pires de Sousa M, Agrawal T (2016) Handbook of low-level laser therapy: Pan Stanford Publishing, pp. 1133
    1. Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy — an update. Dose Response. 2011;9(4):602–618. doi: 10.2203/dose-response.11-009.Hamblin.
    1. Courtois E, Bouleftour W, Guy JB, et al. Mechanisms of PhotoBioModulation (PBM) focused on oral mucositis prevention and treatment: a scoping review. BMC Oral Health. 2021;21(1):220. doi: 10.1186/s12903-021-01574-4.
    1. Fekrazad R, Chiniforush N. Oral mucositis prevention and management by therapeutic laser in head and neck cancers. J Lasers Med Sci. 2014;5(1):1–7.
    1. Begaud B (1998) Dictionnaire de Pharmaco-épidémiologie. 3e édition: Bordeaux
    1. Bjordal JM, Bensadoun RJ, Tuner J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19(8):1069–1077. doi: 10.1007/s00520-011-1202-0.
    1. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS ONE. 2014;9(9):e107418. doi: 10.1371/journal.pone.0107418.
    1. Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, Meyer S (2010) Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (8):CD001973
    1. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):333–341. doi: 10.1007/s00520-012-1605-6.
    1. Bensadoun RJ, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol. 2012;24(4):363–370. doi: 10.1097/CCO.0b013e328352eaa3.
    1. Bensadoun RJ, Epstein JB, Nair RG et al (2020) Safety and efficacy of photobiomodulation therapy in oncology: a systematic review. Cancer Med 9(22):8279–8300
    1. Courtois E, Guy JB, Axisa F, et al (2021) Photobiomodulation by a new optical fiber device: analysis of the in vitro impact on proliferation/migration of keratinocytes and squamous cell carcinomas cells stressed by X-rays. Lasers Med Sci 36(7):1445–1454
    1. Ueno T, Zenda S, Konishi T, et al. The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. Int J Clin Oncol. 2019;24(3):241–247. doi: 10.1007/s10147-018-1355-7.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner